Silence Therapeutics (SLN) Gross Margin: 2020-2025
Historic Gross Margin for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to 59.75%.
- Silence Therapeutics' Gross Margin rose 20267.00% to 59.75% in Q3 2025 from the same period last year, while for Sep 2025 it was 91.32%, marking a year-over-year increase of 4708.00%. This contributed to the annual value of 72.70% for FY2024, which is 1336.00% up from last year.
- Per Silence Therapeutics' latest filing, its Gross Margin stood at 59.75% for Q3 2025, which was down 3.71% from 62.05% recorded in Q2 2025.
- Silence Therapeutics' 5-year Gross Margin high stood at 91.95% for Q4 2024, and its period low was -322.12% during Q2 2024.
- Over the past 3 years, Silence Therapeutics' median Gross Margin value was 61.97% (recorded in 2025), while the average stood at 11.43%.
- In the last 5 years, Silence Therapeutics' Gross Margin crashed by 39,103bps in 2024 and then skyrocketed by 38,418bps in 2025.
- Over the past 5 years, Silence Therapeutics' Gross Margin (Quarterly) stood at 40.19% in 2021, then slumped by 2,117bps to 19.01% in 2022, then skyrocketed by 1,686bps to 35.87% in 2023, then soared by 5,607bps to 91.95% in 2024, then skyrocketed by 20,267bps to 59.75% in 2025.
- Its Gross Margin was 59.75% in Q3 2025, compared to 62.05% in Q2 2025 and 61.97% in Q1 2025.